Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 6/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.31 |
| ▸ | POLB | P06746 | 3/20 | 0.31 |
| ▸ | NPFFR1 | Q9GZQ6 | 2/20 | 0.30 |
| ▸ | NPFFR2 | Q9Y5X5 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4199301 | 1.00 | MEN1 (0.33) | MEN1KMT2ATDP1ATMCYP3A4 | |
| SCHEMBL4198051 | 0.95 | MEN1 (0.32) | MEN1KMT2ATDP1ATMCYP3A4 | |
| SCHEMBL5000816 | 0.95 | — | — | |
| SCHEMBL4198052 | 0.95 | MEN1 (0.32) | MEN1KMT2ATDP1ATMCYP3A4 | |
| SCHEMBL5009492 | 0.90 | — | — | |
| SCHEMBL4198044 | 0.90 | — | — | |
| SCHEMBL4198045 | 0.82 | — | — | |
| SCHEMBL4193786 | 0.79 | MEN1 (0.38) | MEN1KMT2ATDP1ATMCYP3A4 | |
| SCHEMBL4206277 | 0.78 | MEN1 (0.34) | MEN1KMT2ATDP1ATMNPSR1 | |
| SCHEMBL5493413 | 0.77 | RAB9A (0.31) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090012054-A1 | Cephem Compounds and Use as Antimicrobial Agents | ASTELLAS PHARMA INC. (JP) | 2009-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012054-A1 | Cephem Compounds and Use as Antimicrobial Agents | CEP170, Q6ZSR9, H1-10 | MEN1 590/4885KMT2A 2117/4885TDP1 4453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.